See more : Van de Velde NV (0IWV.L) Income Statement Analysis – Financial Results
Complete financial analysis of AVROBIO, Inc. (AVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVROBIO, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Svarnim Trade Udyog Limited (SNIM.BO) Income Statement Analysis – Financial Results
- Modella Woollens Limited (MODWOOL.BO) Income Statement Analysis – Financial Results
- Amphenol Corporation (0HFB.L) Income Statement Analysis – Financial Results
- Danieli & C Officine Meccaniche (DANM.XD) Income Statement Analysis – Financial Results
- KEC International Limited (KEC.NS) Income Statement Analysis – Financial Results
AVROBIO, Inc. (AVRO)
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 47.08M | 72.19M | 83.11M | 87.24M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 22.69M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Selling & Marketing | 23.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.97M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Other Expenses | 0.00 | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -19.00K | -6.00K |
| Operating Expenses | 71.05M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Cost & Expenses | 71.67M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 299.00 | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 2.42M | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00K | 1.44M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 39.00K |
| EBITDA | -71.05M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.04M | -4.59M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.67M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | 12.53M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 157.00K | -1.40M | -1.21M | -850.00K | -118.00K | 243.00K | -6.00K |
| Net Income | 12.16M | -106.05M | -117.73M | -118.51M | -72.12M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| EPS Diluted | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| Weighted Avg Shares Out | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
| Weighted Avg Shares Out (Dil) | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio (NASDAQ: AVRO ) stock is on the move Thursday as the company is preparing for two major events taking place today. The first thing to note is that Avrobio is getting ready to undergo a merger with Tectonic Therapeutic.
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. “Dan is an experienced public-company CFO who will add significant...
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which...
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which...
Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic
MILWAUKEE , Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic. Click here to learn how to join the https://www.ademilaw.com/case/avrobio-inc...
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO shareholders. Upon completion of the proposed transaction, pre-merger AVROBIO shareholders are expected...
AVROBIO and Tectonic Therapeutic Announce Merger
CAMBRIDGE, Mass. & WATERTOWN, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today...
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports